Return to homepagePandemic Pact

Functional characterization of cross-reactive and specific antibodies against highly-pathogenic avian influenza at human/wildlife interface

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 507226

Grant search

Key facts

  • Disease

    Influenza caused by Influenza A virus subtype H5

  • start year

    2024

  • Known Financial Commitments (USD)

    $109,608.3

  • Funder

    Canadian Institutes of Health Research (CIHR)

  • Principal Investigator

    Khaperskyy Denys

  • Research Location

    Canada

  • Lead Research Institution

    Dalhousie University (Nova Scotia)

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Indigenous People

  • Occupations of Interest

    Unspecified

Abstract

The goal of our proposed research is to establish a robust system for functionally assessing antibody-mediated immunity to H5N1 HPAI in animals and humans, acquired through immunization or prior infections, including cross-protective immunity from antibodies against other influenza A virus subtypes. We are going to achieve this goal through three research aims: Aim 1. Develop research team capacity for an integral Indigenous (First Nations, Inuit, and Metis) lens on a One Health highly pathogenic influenza discovery research team. Aim 2. Establish and validate a pseudo neutralization assay to measure neutralizing antibodies to clade 2.3.4.4b H5 hemagglutinin. Aim 3. Establish and validate functional assays to measure protective and cross-protective antibodies to HA and NA of HPAI in humans.